|Home | About | Journals | Submit | Contact Us | Français|
Although many underlying diseases have been reported in the setting of childhood arterial ischemic stroke, emerging research demonstrates that non-atherosclerotic intracerebral arteriopathies in otherwise healthy children are prevalent. Minor infections may play a role in arteriopathies that have no other apparent underlying cause. Although stroke in childhood differs in many aspects from adult stroke, few systematic studies specific to pediatrics are available to inform stroke management. Treatment trials of pediatric stroke are required to determine the best strategies for acute treatment and secondary stroke prevention. The high cost of pediatric stroke to children, families, and society demands further study of its risk factors, management, and outcomes. This review focuses on the recent findings in childhood arterial ischemic stroke.
Tremendous efforts have been made to increase public recognition of adult stroke, yet pediatric stroke remains under-recognized even among health care providers. However, pediatric stroke is an important cause of lifelong disability. A recent population-based study of stroke in children less than 20 years of age estimates an annual rate of 2.4 arterial ischemic strokes per 100,000 children . Large-scale studies of pediatric stroke have begun to advance our understanding of underlying risk factors, but little research is currently available to guide decision making about acute management and secondary stroke prevention. Many of these children are left with permanent neurologic deficits and epilepsy, and pediatric stroke incurs a high cost to families and societies. Although pediatric stroke includes arterial ischemic stroke, hemorrhagic stroke, and venous thrombosis, hemorrhage and venous thromboses are beyond the scope of this brief update.
Overall, presumptive risk factors for arterial ischemic stroke differ in children compared with adults. Whereas adult risk factors are primarily related to arrhythmias and obstructive atherosclerotic arteriopathies, these are rarely thought to be related to stroke in children. Also in contrast to adults, socioeconomic status has not been shown to be associated with an increased stroke risk in children . Interestingly, just as gender differences are found in adult stroke studies, several pediatric studies have shown a male predominance in children with a stroke [2, 3]. Among boys, elevated testosterone levels were independently associated with stroke risk . The mechanism of this association is still unknown. In the International Pediatric Stroke Study (IPSS) and other studies of pediatric stroke, a wide range of underlying systemic factors were reported in the setting of childhood stroke, particularly sickle cell disease, cardiac disorders, trauma, and major infections such as meningitis, sepsis, and encephalitis . However, in the majority of the children, no underlying systemic disease is found. With advances in neuroimaging, cerebral arteriopathies are increasingly recognized as one of the major causes of childhood stroke in otherwise healthy children [6, 7•]. Although the importance of arteriopathies is highlighted in this review, advances in understanding of sickle cell disease, cardiac disease, and prothrombotic disorders are also discussed.
The IPSS recently reported on presumptive risk factors in their case series of 667 children from five continents that have had a stroke . In the study, 53% of the children who had vascular imaging were found to have an arteriopathy [7•]. Some arteriopathies are due to well-recognized causes such as arterial dissection, moyamoya syndrome or disease, connective tissue disorders, and sickle cell disease. Late effects of radiation to the head and neck in childhood cancer survivors have also been associated with stroke due to cerebrovascular disease, and children with neurofibromatosis can have complications of a cerebral arteriopathy . However, in up to 30% of children presenting with a first arterial ischemic stroke, a focal arterial stenosis is identified but none of the classic underlying causes are discovered.
The term “transient cerebral arteriopathy” (TCA) was first used to describe a common course of cerebrovascular pathology in a group of children with ischemic stroke who received serial imaging studies . In this group, focal stenoses or segmental narrowing of the cerebral arterial wall, characteristically involving the distal internal cerebral artery, proximal middle cerebral artery, and sometimes the proximal anterior cerebral artery, were followed over time with serial angiograms (Fig. 1). The term “transient” was used because of the monophasic progression of cerebrovascular disease. In children with TCA, the arterial stenosis and narrowing is strictly unilateral and may initially worsen. In some cases, no abnormality is noted on initial vascular imaging, but stenosis or occlusion is seen on follow-up imaging within the first few months. However, after the first 6 months, the arteriopathy stabilizes and sometimes improves. In some sense, the term “transient” cerebral arteriopathy is somewhat misleading. Although monophasic in the progression of stenosis, in many cases the arterial narrowing persists on long-term follow-up imaging.
On initial imaging studies, TCA cannot be distinguished from a progressive arteriopathy such as moyamoya disease or a vasculitis that presents unilaterally. Worsening after 6 months or bilateral involvement suggests an arteriopathy other than TCA, with a different course and prognosis. In recognition of the limitations of classifying arteriopathies on initial imaging, the IPSS has recently suggested the term “focal cerebral arteriopathy” of childhood (FCA) to describe children with unilateral arterial stenosis without an apparent underlying cause at presentation [7•]. Both the terms TCA and FCA are simply descriptive and do not imply a specific pathophysiology; however, these arteriopathies are clinically important because they indicate an increased risk for recurrent stroke [6, 10, 11]. In all children who have had a stroke, vascular imaging of intracranial and neck vessels is imperative to detect arteriopathies, with magnetic resonance angiography (MRA) as the preferred modality. However, if interventional neuroradiologists who have an expertise in pediatrics are available, conventional angiography can be considered in cases in which diagnosis remains unclear on MRA. In addition, even in children with a stable clinical course, MRI and vascular imaging should be repeated 3–6 months after the acute stroke and again 1 year later to detect development of or changes in arteriopathies, as well as to look for new subclinical infarcts.
Currently, the underlying mechanisms for these unilateral, monophasic arteriopathies are poorly understood, and studies are ongoing to elucidate their pathophysiology. The role of infection as a part of the underlying vascular pathology is of particular current interest. The link between childhood stroke and infection was first noted because of its temporal association with varicella infection; post-varicella angiopathy has been well described as a cause for ischemic stroke in both adults and children [12, 13]. Importantly, no association has been found with varicella vaccination . Multiple viruses other than varicella have been linked to case reports of arteriopathies and stroke in children. Strengthening the infectious hypothesis, the IPSS reported finding an association between childhood arteriopathies and recent minor infections in their large cohort of children with ischemic stroke [7•]. In the study, 25% of the children were classified as having FCA, higher in frequency than either moyamoya (22%) or dissection (20%). Predictors of overall arteriopathies were early school age (5–9 years), recent upper respiratory infections, and sickle cell disease. The only predictor of FCA was a recent upper respiratory infection (odds ratio [OR]=2.1; 95% CI, 1.01–4.38). The role of minor infections in the pathogenesis of stroke has been suggested either as a cause of direct vascular injury, or by inducing a systemic prothrombotic state, or through both mechanisms. However, minor infections are extremely common in young children, and yet most children do not have strokes. More study is needed to clarify how infection contributes to arteriopathies and stroke.
Children with sickle cell disease comprise another important group with a high risk of arteriopathies and stroke. Prior to modern primary prevention strategies, up to 11% of children with sickle cell anemia had a clinical stroke by the age of 20 years . In 1992, transcranial Doppler (TCD) was found to be effective in identifying patients with sickle cell disease at high risk for stroke . The Stroke Prevention Trial in Sickle Cell Anemia (STOP) established that chronic transfusion decreased the risk of stroke by 90% in children with abnormal TCD results , leading to recommendations for chronic transfusion for prevention of stroke in children deemed at high risk. However, TCD screening in sickle cell disease continues to be examined for feasibility and efficacy internationally [18, 19], and barriers to care persist. A recent study of children in northern California showed the rate of stroke in children with sickle cell disease has dropped by more than half the rate prior to 1998, but also demonstrated that children living farther from a vascular laboratory are less likely to be screened . Finally, although stroke risk in people with sickle cell disease is usually attributed to red cell sickling and vasculopathy of large intracranial vessels, new concerns have recently been raised for an increased risk for cardioembolic stroke in these children because of the potential for increased right heart pressure and right-to-left shunting in the setting of a prothrombotic state .This suggests the intracardiac shunts in children with sickle cell disease should be further studied as a potentially modifiable cause of stroke. Current American Heart Association stroke prevention screening recommendations in sickle cell disease are for annual TCD monitoring of children with normal TCD velocities (≤170 cm/s), with consideration of more frequent monitoring in children 2 to 10 years of age. Children with velocities elevated to ≥200 cm/s should be restudied in 1 month, and studies with borderline or mildly abnormal results should be repeated in 3–6 months. Periodic transfusions to reduce the percentage of sickle hemoglobin are recommended in children with abnormal TCD results [22••].
Congenital heart disease and other cardiac problems are still recognized as presumed risk factors for childhood stroke because of their high frequency in case series . A case-control study of children in northern California demonstrated an increased risk for children with congenital heart disease requiring surgical repair (OR=11; 95% CI, 3.1–39.4) (Fox and Fullerton, unpublished data). Even with modern surgical techniques, the peri-operative period may be of particularly high risk, as demonstrated in a recent series of 122 children undergoing open heart surgery, which identified stroke in 10% [22••]. However, children with complex congenital heart disease remain at risk for years after their last surgery, which reflects increased stroke risk from the heart disease itself. When feasible, complex congenital heart lesions should be repaired to improve cardiac function and reduce the risk of subsequent stroke [22••].
Finally, controversies remain over the strength of association of hypercoaguable disorders as a risk for childhood stroke. Homozygosity for MTHFR C677T polymorphism did not show an increased risk for arterial ischemic stroke in two recent studies of stroke in children in the United States  and Croatia , but a study in Poland  found a threefold increased risk of stroke with the presence of the MTHFR C677T allele. Factor V G1691A was associated with a sevenfold increased risk among children with stroke in the Croatian study . Although various coagulation abnormalities have been reported in children after stroke, most pediatric stroke experts believe the likelihood of stroke from most prothrombotic states seems to be relatively low. However, the risk may tend to increase in the setting of additional risk factors. Children with a stroke who are found to have a prothrombotic polymorphism or other prothrombotic state should have additional workup including serial vascular imaging to determine etiology. Although there are no class I recommendations regarding hypercoaguable states in childhood stroke, it is reasonable to evaluate for elevated serum homocysteine levels and the more common prothrombotic states, and start folate, vitamin B6, or vitamin B12 if homocysteine is found to be elevated. It is also reasonable to discontinue oral contraceptives in adolescents after an ischemic or thrombotic stroke .
Acute management of children with stroke is primarily supportive, including control of fever, blood pressure normalization to accepted age ranges, normalization of glucose, and maintenance of normal oxygenation. For secondary stroke prevention, the majority of children are treated with either anticoagulation or antiplatelet therapies, and current practice varies widely. Overall, the great variety of treatment strategies emphasizes the need for better evidence and clinical trials to guide management of childhood stroke.
Of the children enrolled in the IPSS who had a non-neonatal arterial ischemic stroke, 27% of children were treated with anticoagulation alone, 28% were treated with antiplatelet therapy alone, and 16% were treated with both anticoagulation and antiplatelet therapies . Predictors of anticoagulation were dissection and cardiac disease. This parallels recent American Heart Association guidelines [22••] and American College of Chest Physicians guidelines [28••] for consideration of anticoagulation in children in the setting of confirmed cardio-embolism or arterial dissection. Because the risk for recurrence is relatively high in children who have arteriopathies, there has been some interest in exploring the safety of anticoagulation in this setting. A nonrandomized, unblinded study from the Colorado and German (COAG) collaboration examined both therapeutic and prophylactic dosing of anticoagulation therapy for stroke in children with non-moyamoya arteriopathy, with only two clinically relevant bleeding episodes in 1329 patient-months . The relatively low risk of bleeding suggests that anticoagulation could be safely studied in future trials.
Although tissue plasminogen activator (tPA) has changed the face of adult stroke treatment, there have been no randomized controlled trials of therapeutics in childhood arterial ischemic stroke. A special writing group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young has recently published an extensive review of the literature on childhood stroke with consensus guidelines for the management of stroke in infants and children [22••]. In that review, there was no consensus about the use of tPA in older adolescents who otherwise met standard adult tPA eligibility criteria. In younger children, tPA was not recommended outside of a clinical trial. In the IPSS observational cohort of children with acute arterial ischemic stroke, 2% of the children received either intravenous or intra-arterial tPA, at a median time of 3.3 h or 4.5 h, respectively. Of these 15 patients, new or increased intracerebral hemorrhage was found in four, and the recurrent stroke rate at 1 year was 14% . In addition, a recent literature review described a series of 17 children who had received intravenous, intra-arterial, or mechanical thrombolysis for large vessel strokes; 16 children survived and 12 had a good outcome .
The appropriate dosage of tPA in various age groups remains an unknown, and extrapolation from adult data is complicated by age-related differences in coagulation systems. Thus far, there are no systematic data to guide the age-appropriate use of tPA in children, and clinical trials are needed to explore safety and efficacy in this population. The Thrombolysis in Pediatric Stroke (TIPS) trial is in planning stages; it aims to test the hypothesis that tPA can be given safely in acute childhood arterial ischemic stroke and establish dosing guidelines . However, conducting a clinical trial in a vulnerable population can present significant challenges. In addition, because few pediatric strokes are diagnosed quickly enough to consider a thrombolytic agent, trials of acute intervention may have slow accrual. Although public health campaigns have successfully raised awareness about stroke in adults, awareness of pediatric stroke remains limited. Children often present late to medical care, and even after medical evaluation have significant delays in diagnosis. Although the majority of children with stroke present with focal findings such as hemiparesis , nonspecific presenting signs such as altered mental status, seizure, and headache are also frequently reported. One recent study of childhood arterial ischemic stroke (excluding neonatal stroke) in Australia found a median time of greater than 24 h after clinical onset before radiologic confirmation of diagnosis . In this study, only 6.8% of the children were diagnosed with a stroke within 3 h. In the United Kingdom , Canada , and the United States , similar time delays have been reported. Nonspecific presentation and the perception that childhood stroke is rare both contribute to initial misdiagnoses that result in delays in management. Raising awareness of pediatric stroke is crucial to improving overall care of these children.
Pediatric stroke is an important cause of childhood morbidity and lifelong disability, including motor and sensory impairments, cognitive deficits, and epilepsy. In the IPSS cohort, after arterial ischemic stroke 74% of patients had neurologic deficits at hospital discharge and 3% of the children had died . Long-term outcomes for children in the IPSS are not yet available. Although physical, occupational, and speech therapies are mainstays to improve function in children with neurologic deficits after a stroke, pediatric-specific research regarding different methods of rehabilitation is lacking.
Overall, clinical stroke recurrences are seen in an estimated 6–15% of children after a first arterial ischemic stroke, but the risk of recurrence depends on stroke etiology. Braun et al. [36•] described a series of 79 children found to have an intracranial unilateral arteriopathy after a stroke. In 74 of the children, the arteriopathy stabilized or improved and was categorized as TCA, although 77% of these had residual vascular abnormalities. Recurrent stroke or transient ischemic attack occurred in 18% of the children categorized as TCA after a median follow-up of 1.4 years. Progressive arteriopathies were associated with recurrence (OR=18.7; 95% CI, 1.9–182). In the COAG cohort, children with non-moyamoya arteriopathies were given various treatments of prophylactic or therapeutic anticoagulation, and cumulative probability of recurrent stroke was 14% at 1 year . These recent findings build on prior studies that found abnormal vascular imaging predicts recurrence . Systematic studies of secondary stroke prevention in children with arteriopathies are not yet available, and clinical trials are needed to determine the best treatment strategies.
In comparison with the low risk of epilepsy after stroke in adults, estimated at 2–4% , the risk of epilepsy after childhood stroke maybe an order of magnitude higher, with some estimates as high as 67% after a neonatal stroke . Follow-up studies of stroke later in childhood give estimates of epilepsy ranging from 25 to 30% . Although the frequency of epilepsy after childhood stroke reported in these case series is worrisome, the estimates of post-stroke epilepsy prevalence are wide ranging and there are few data regarding predictors of epilepsy to alert physicians to high-risk groups. More research is required to determine the incidence and predictors of epilepsy in these children.
Epilepsy after pediatric stroke is particularly worrisome because of the additional morbidities reported in children who have seizures after brain injury. After a stroke, children are already at risk for behavioral and psychiatric problems . In turn, attention deficit hyperactivity disorder (ADHD) can further impair school performance, particularly in children whose cognitive functioning may already be compromised. Recent studies have suggested that children with epilepsy after a childhood stroke maybe at particular risk for behavioral and psychiatric co-morbidities such as ADHD and depression, and it may herald worse neurocognitive outcomes [41, 42]. Some researchers theorize that seizures after a stroke in the developing brain may change the brain’s capacity for plasticity. However, it is not known whether the risk for poor behavioral and cognitive outcomes that we have begun to recognize in these children maybe due to presence of seizures, the medications to treat the seizures, or whether the seizures are simply a marker of inherent capacity in children with more severe brain injury.
Infarct size and altered mental status at presentation predict long-term outcome of pediatric stroke [27, 43, 44]. However, these broad measures still leave physicians and families with little to guide their expectations for the future. Children with neonatal stroke may not manifest hemiparesis until months after birth, and a few studies have focused on finding earlier predictors of outcome. One study of 13 children after a neonatal stroke examined hand movements at 3 months of age. The study found asymmetric hand movements could be determined with good inter-observer agreement, and it predicted later hemiplegia in 13 children . Researchers are also studying imaging techniques as a way to provide earlier prognostication. Novel imaging techniques using measurements of diffusion MRI found pre-Wallerian degeneration of corticospinal tracts to be predictive of poor motor outcome after neonatal  and pediatric  stroke. Although these diffusion-weighted imaging quantification techniques are not yet routinely used, in the future similar imaging techniques may provide better prognostication. A more accurate assessment of outcome at early time points after a childhood stroke would be helpful both for family expectations and for selection of patients in trials of therapeutic interventions.
In terms of the economic burden of stroke care, adult stroke has been analyzed extensively for cost-effectiveness of interventions. A 2009 review of 120 cost studies of adult ischemic and hemorrhagic stroke from 15 countries found the mean cost of adult stroke was $19,018, but varied as much as 20-fold in the United States estimates . In contrast, fewer studies have examined the cost of pediatric stroke. Two recent studies have estimated acute and long-term costs of childhood stroke in 2003 dollars. The mean cost of acute hospital care for pediatric stroke was high, estimated at $20,927 per discharge in 2003 using a national database of ICD-9 codes (the Kids’ Inpatient Database) for both ischemic and hemorrhagic stroke . Hemorrhagic stroke, geographic data, urban teaching hospitals, and discharge disposition were predictors of higher cost. In a Northern California health maintenance organization, the average coast of a childhood acute stroke admission was $90,693 for hemorrhagic stroke and $36,073 for ischemic stroke. In the same cohort, the average cost of birth admission for a neonatal stroke was $39,613 . When costs were adjusted for a stroke-free birth admission, cost of the stroke was estimated to account for 88% of the admission cost. In addition, direct medical costs for inpatient and outpatient health services over 5 years were estimated to be $51,719 for neonatal stroke and $135,161 overall in the Northern California cohort. These studies suggest that the financial cost of pediatric stroke is high, and that the economic burden of medical care for these children continues for many years after the acute hospitalization.
Childhood arterial ischemic stroke differs from adult stroke in risk factors, etiologies, and outcomes. Recent studies have focused attention on the importance of non-atherosclerotic arteriopathies and recent infection. Although the causes of pediatric stroke are very different from adult stroke, many of the current therapeutic strategies and secondary stroke prevention with antiplatelets or anticoagulation are adapted from adult stroke management. Little is known about the safety and efficacy of acute thrombolytic therapies in various age groups. Finally, long-term outcomes of pediatric stroke are difficult to predict, but overall place a large burden on stroke victims, families, and society. Further study is greatly needed for a better understanding of the pathogenesis, management, and outcomes in childhood arterial ischemic stroke.
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
Christine K. Fox, Phone: +415-476-2027, Fax: +415-476-2500, Email: ude.fscu.sdeporuen@cxof.
Heather J. Fullerton, Phone: +415-353-3681, Fax: +415-476-2500, Email: ude.fscu.sdeporuen@hnotrelluf.